AMY RIVAS: Open Payments
NPI 1699244830 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,716 in 222 payments from 29 companies in 2025. Trend: 2023 $1,023 · 2024 $4,691 · 2025 $7,716
Food & beverage: $6,530Travel & lodging: $1,186
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. | 35 | $2,413 |
| Sequel Med Tech, LLC | 26 | $746 |
| Novo Nordisk Inc | 21 | $683 |
| Amgen Inc. | 16 | $475 |
| Lilly USA, LLC | 20 | $458 |
| Corcept Therapeutics | 15 | $450 |
| Insulet Corporation | 7 | $377 |
| Madrigal Pharmaceuticals | 7 | $349 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $267 |
| Tandem Diabetes Care, Inc. | 5 | $198 |
Products named: MINIMED 780G, TWIIST, INPEN SMART INSULIN DELIVERY SYSTEM, Korlym, JARDIANCE, Omnipod, REZDIFFRA, Ozempic.
Industry payments across TX — which companies pay providers there.
